Pedro de Noronha Pissarra, chief executive officer of Biotecnol said: «We're very proud to work with Cancer Research UK on the development of advanced clinical trial approaches in this competitive and highly promising field of immuno - oncology.
Under the terms of the new agreement, AstraZeneca and Moderna, a pioneer of mRNA Therapeutics ™, have agreed to collaborate on two specific immuno - oncology programs, based on promising pre-clinical data, including pharmacology in tumor models.
Circulating autoantibodies are powerful resources to aid in the diagnosis and treatment of autoimmune disorders, infectious diseases and cancer - especially with promising advances in immuno - oncology.